In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Appointments at Cadence Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Cadence Pharmaceuticals (US) has appointed Dr Todd Rich to the company's board of directors and named Malcolm Lloyd-Smith senior vice-president of regulatory affairs and quality assurance. Mr Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company; he was previously vice-president and head of global regulatory affairs at Elan Pharmaceuticals. Dr Rich is vice-president of development regulatory, medical information, drug safety, quality and compliance at Genentech.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel